Modulating the terminal unfolded protein response


Founded in 2014, OptiKira is advancing discoveries made by a team from The University of California, San Francisco and the University of Washington. Extensive research by our academic founders has helped define the biological pathway leading to progressive cell death which characterizes diseases such as retinitis pigmentosa, diabetes, and amyotrophic lateral sclerosis (ALS).



Read more on the development of our novel therapeutics.

Learn More →


Get to know our drug development experts.

Learn More →